Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARG | Q86W56 | 4/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10145920 | 0.84 | PARG (0.46) | PARGGRIN1GRIN2BGRM2CRHR1 | |
| SCHEMBL14992462 | 0.83 | GRM2 (0.60) | PARGBACE1CYP11B1CYP11B2GRM2 | |
| SCHEMBL14992395 | 0.82 | PARG (0.47) | PARGBACE1GSK3BDYRK1ABACE2 | |
| SCHEMBL627472 | 0.81 | GRM2 (0.49) | BACE1GSK3BDYRK1ABACE2CYP11B1 | |
| SCHEMBL14992315 | 0.79 | GRM2 (0.42) | BACE1GSK3BDYRK1ABACE2CYP11B1 | |
| SCHEMBL626976 | 0.78 | PARG (0.41) | PARGGRM2PRMT5WDR77 | |
| SCHEMBL626276 | 0.77 | PARG (0.41) | PARGCREBBPKDM1AGRM2 | |
| SCHEMBL10146576 | 0.77 | GRM2 (0.64) | PARGGRIN1GRIN2BGRM2CRHR1 | |
| SCHEMBL627523 | 0.76 | PARG (0.45) | PARGCYP11B2KDM1AGRM2CRHR1 | |
| SCHEMBL14992698 | 0.76 | PARG (0.45) | PARGGRM2CRHR1CRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2603079-B1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME (US) | 2018-09-19 | — | — | EP | claimed |
| US-8993779-B2 | Positive allosteric modulators of MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | claimed |
| EP-2603079-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | Merck Sharp & Dohme Corp. (US) | 2013-06-19 | — | — | EP | claimed |
| US-20130143880-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME LLC | 2013-06-06 | — | — | US | claimed |
| WO-2012021382-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2012-02-16 | — | — | WO | claimed |
| EP-2603079-B1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME (US) | 2018-09-19 | — | — | EP | disclosed |
| US-8993779-B2 | Positive allosteric modulators of MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993779-B2 | Positive allosteric modulators of MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993779-B2 | Positive allosteric modulators of MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20130143880-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME LLC | 2013-06-06 | — | — | US | disclosed |
| US-20130143880-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME LLC | 2013-06-06 | — | — | US | disclosed |
| US-20130143880-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME LLC | 2013-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143880-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | GRM2, GRIA2, GRM1 | PARG 4723/4885BACE1 3135/4885GSK3B 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.